Notably, around 45%–50% of brain cholesterol turnover is regulated by the brain-specific enzyme CYP46A1 (80–85), offering a disease-modifying approach by regulating cholesterol homeostasis that emerged as a potential therapeutic strategy for neurodegenerative diseases, including prion diseases. Here, CYP46A1 is linked to prion disease.